Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PTAFR | P25105 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 2/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825782 | 0.92 | KDM4E (0.30) | — | |
| SCHEMBL15809177 | 0.89 | NPC1 (0.30) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL17403189 | 0.86 | — | — | |
| SCHEMBL15808721 | 0.83 | — | — | |
| SCHEMBL17120310 | 0.83 | CYP19A1 (0.32) | — | |
| SCHEMBL15809253 | 0.82 | TDO2 (0.32) | — | |
| SCHEMBL20165813 | 0.82 | — | — | |
| SCHEMBL29675202 | 0.82 | — | — | |
| SCHEMBL15809414 | 0.79 | KDM4E (0.33) | — | |
| SCHEMBL31099225 | 0.78 | RXRB (0.32) | RXRBRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160002369-A1 | CATALYSTS | BOREALIS AG (AT) | 2016-01-07 | — | — | US | disclosed |
| US-20160002369-A1 | CATALYSTS | BOREALIS AG (AT) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002369-A1 | CATALYSTS | SIGMAR1, SFN, AP3S1 | NPC1 2300/4885LMNA 2545/4885TP53 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.